阿卡波糖联合二甲双胍对2型糖尿病伴冠心病患者的临床疗效

The clinical efficacy of acarbose and metformin in the treatment of type 2 diabetes mellitus patients with coronary heart disease

目的:探讨阿卡波糖联合二甲双胍治疗2型糖尿病伴冠心病患者的临床效果。方法:2010年2月-2012年12月收治2型糖尿病伴冠心病患者98例,随机分为对照组和观察组,各49例。对照组给予二甲双胍进行治疗,观察组给予阿卡波糖与二甲双胍联合治疗,两组患者均接受12周治疗。治疗结束后对两组患者空腹血糖、餐后2 h血糖、超敏C反应蛋白、颈动脉内膜中层厚度进行复查,比较两组的治疗效果。结果:两组患者治疗后血糖、超敏C反应蛋白(hs-crp)、颈动脉内膜中层厚度(IMT)比较差异有统计学意义(P<0.05),两组在治疗期间均未出现严重不良反应,两组比较差异无统计学意义(P>0.05)。结论:阿卡波糖联合二甲双胍对于2型糖尿病伴冠心病患者的治疗效果显著,可改善冠心病的预后,且安全有效,值得在临床上广泛推广和使用。

Objective:To investigate the clinical efficacy of acarbose and metformin in the treatment of type 2 diabetes mellitus patients with coronary heart disease.Methods:98 cases of type 2 diabetes mellitus complicated with coronary heart disease were selected from February 2010 to December 2012.They were randomly divided into the control group and the observation group with49 cases in each.Patients in the control group were given metformin treatment.Patients in the observation group were received acarbose and metformin treatment.Both of the groups were treated for 12 weeks.After the treatment,the fasting blood glucose,2hours postprandial blood glucose,high sensitive C reactive protein and carotid artery intima-media thickness of patients in 2groups were reviewed,then we compared the treatment effect of 2 groups.Results:After the treatment,the difference in blood sugar,high sensitive C reactive protein(hs-CRP) and carotid artery intima-media thickness(IMT) were statistically significant between the two groups(P<0.05);there were no serious adverse reactions during the treatment,and the differences was no significant between the two groups(P>0.05).Conclusion:Acarbose and metformin treated on patients with type 2 diabetes mellitus complicated with coronary heart disease can achieved remarkable curative effect,and can improve the prognosis of coronary heart disease.It is safe and effective.So it is worthy of extensive promotion and clinical use.